Dynasty Wealth Management LLC Makes New $214,000 Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Dynasty Wealth Management LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, Holdings Channel.com reports. The firm bought 396 shares of the company’s stock, valued at approximately $214,000.

Several other hedge funds have also recently bought and sold shares of IDXX. Waypoint Capital Advisors LLC bought a new stake in IDEXX Laboratories during the fourth quarter valued at about $222,000. Nvest Financial LLC boosted its holdings in IDEXX Laboratories by 48.2% during the fourth quarter. Nvest Financial LLC now owns 1,607 shares of the company’s stock valued at $892,000 after acquiring an additional 523 shares during the period. Financial Management Network Inc. bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $224,000. State of Michigan Retirement System lifted its stake in shares of IDEXX Laboratories by 0.5% in the fourth quarter. State of Michigan Retirement System now owns 41,455 shares of the company’s stock valued at $23,010,000 after buying an additional 200 shares during the period. Finally, Colonial River Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $554,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $476.12 on Thursday. The firm has a market cap of $39.32 billion, a price-to-earnings ratio of 46.09, a PEG ratio of 3.89 and a beta of 1.32. The company has a 50 day moving average of $490.75 and a 200-day moving average of $515.59. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. The company had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.11% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on IDXX. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. BTIG Research began coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Finally, Barclays cut their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $585.89.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.